Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma

被引：0

作者：

Manfredi, G. F. ^{[1
,2
]}

Fulgenzi, C. A. M. ^{[2
]}

D'Alessio, A. ^{[2
,3
]}

Celsa, C. ^{[2
,4
,5
]}

Stefanini, B. ^{[2
,6
]}

Cheon, J. ^{[7
]}

Ang, C. ^{[8
]}

Marron, T. U. ^{[8
]}

Saeed, A. ^{[9
]}

Wietharn, B. ^{[9
]}

Pressiani, T. ^{[10
]}

Pinter, M. ^{[11
]}

Scheiner, B. ^{[11
]}

Huang, Yi-Hsiang ^{[12
,13
]}

Phen, S. ^{[14
]}

Naqash, A. Rafeh ^{[15
]}

Piscaglia, F. ^{[6
]}

Lin, R. Po-Ting ^{[16
,17
]}

Lin, C. -yen ^{[16
,17
]}

Dalbeni, A. ^{[18
,19
]}

Vivaldi, C. ^{[20
,21
]}

Masi, G. ^{[20
,21
]}

Thimme, R. ^{[22
]}

Vogel, A. ^{[23
,24
,25
]}

Schonlein, M. ^{[26
]}

von Felden, J. ^{[27
]}

Schulze, K. ^{[27
]}

Wege, H. ^{[27
]}

Galle, P. R. ^{[28
]}

Kudo, M. ^{[29
]}

Rimassa, L. ^{[10
,30
]}

Singal, A. ^{[14
]}

Sharma, R. ^{[2
]}

Cortellini, A. ^{[1
,31
]}

Chon, H. Jae ^{[7
]}

Burlone, M. ^{[32
]}

Pirisi, M. ^{[1
,32
]}

Pinato, D. J. ^{[2
,3
]}

机构：

[1] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy

[2] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Du Cane Rd, London, England

[3] Univ Piemonte Orientale, Div Oncol, Dept Translat Med, Novara, Italy

[4] Univ Palermo, Sect Gastroenterol & Hepatol, Dept Hlth Promot Mother & Child Care Internal Med, Palermo, Italy

[5] Univ Palermo, Dept Surg Oncol & Oral Sci Di Chir On S, Palermo, Italy

[6] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

[7] CHA Univ, Dept Internal Med, CHA Bundang Med Ctr, Med Oncol, Seongnam, South Korea

[8] Tisch Canc Inst, Mt Sinai Hosp, Div Hematol Oncol, Dept Med, New York, NY USA

[9] Kansas Univ, Div Med Oncol, Dept Med, Canc Ctr, Kansas City, KS USA

[10] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Humanitas Canc Ctr, Via A Manzoni 56, I-20089 Rozzano, Milan, Italy

[11] Med Univ Vienna, Div Gastroenterol & Hepatol, Dept Internal Med 3, Vienna, Austria

[12] Taipei Vet Gen Hosp, Div Gastroenterol & Hepatol, Dept Med, Taipei, Taiwan

[13] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Sch Med, Taipei, Taiwan

[14] Univ Texas Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA

[15] Univ Oklahoma, Med Oncol, Stephenson Canc Ctr, TSET Phase 1 Program, Oklahoma City, OK USA

[16] Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Linkou Med Ctr, Taoyuan, Taiwan

[17] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[18] Univ Verona, Dept Med, Gen Med C Unit, Verona, Italy

[19] Univ Verona, Liver Unit, Verona, Italy

[20] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy

[21] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy

[22] Univ Freiburg, Freiburg Univ Med Ctr, Dept Med Gastroenterol Hepatol Endocrinol & Infec, Fac Med, Freiburg, Germany

[23] UHN, Toronto Gen Hosp, Toronto, ON M5G 2C4, Canada

[24] Princess Margaret Canc Ctr, Toronto, ON, Canada

[25] Hannover Med Sch, Hannover, Germany

[26] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hamburg, Germany

[27] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Hamburg, Germany

[28] Univ Med Ctr Mainz, Dept Internal Med 1, Mainz, Germany

[29] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[30] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20072 Milan, Italy

[31] Fdn Policlin Univ Campus Biomed, Med Oncol, Rome, Italy

[32] AOU Maggiore Carita, Div Internal Med, Novara, Italy

来源：

DIGESTIVE AND LIVER DISEASE | 2024年 / 56卷

关键词：

D O I：

10.1016/j.dld.2024.01.012

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

OC-11

引用

页码：S8 / S9

页数：2

共 50 条

[31] Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study
Kai, Machiko
Hikita, Hayato
Kazuki, Maesaka
Tahata, Yuki
Shinkai, Kazuma
Doi, Akira
Ohkawa, Kazuyoshi
Miyazaki, Masanori
Ishida, Hisashi
Matsumoto, Kengo
Nozaki, Yasutoshi
Yakushijin, Takayuki
Sakamori, Ryotaro
Kaneko, Akira
Iio, Sadaharu
Nawa, Takatoshi
Kakita, Naruyasu
Morishita, Naoki
Hiramatsu, Naoki
Usui, Takeo
Imanaka, Kazuho
Doi, Yoshinori
Sakakibara, Mitsuru
Yoshida, Yuichi
Oze, Tsugiko
Kodama, Takahiro
Tatsumi, Tomohide
Takehara, Tetsuo
PLOS ONE, 2024, 19 (01):
[32] The Impact of Infections in Patients Treated with Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
Esmail, Abdullah
Xu, Jiaqiong
Burns, Ethan A.
Abboud, Karen
Sheikh, Ali
Umoru, Godsfavour
Gee, Kelly
Wiechmann, Catherine
Zhang, Yuqi
Abdelrahim, Maen
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (17)
[33] CLINICAL FACTORS ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA: A MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY
Maesaka, Kazuki
Hikita, Hayato
Kai, Machiko
Tahata, Yuki
Shinkai, Kazuma
Doi, Akira
Ohkawa, Kazuyoshi
Miyazaki, Masanori
Ishida, Hisashi
Matsumoto, Kengo
Nozaki, Yasutoshi
Yakushijin, Takayuki
Sakamori, Ryotaro
Kodama, Takahiro
Tatsumi, Tomohide
Takehara, Tetsuo
HEPATOLOGY, 2023, 78 : S1813 - S1813
[34] Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma
Itoh, Shinji
Ikeda, Masafumi
HEPATOBILIARY SURGERY AND NUTRITION, 2022,
[35] Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
Reika Yamauchi
Takanori Ito
Sachiyo Yoshio
Takafumi Yamamoto
Kazuyuki Mizuno
Masatoshi Ishigami
Hiroki Kawashima
Satoshi Yasuda
Shigeo Shimose
Hideki Iwamoto
Taiji Yamazoe
Taizo Mori
Eiji Kakazu
Takumi Kawaguchi
Hidenori Toyoda
Tatsuya Kanto
Journal of Gastroenterology, 2023, 58 : 565 - 574
[36] Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
Yamauchi, Reika
Ito, Takanori
Yoshio, Sachiyo
Yamamoto, Takafumi
Mizuno, Kazuyuki
Ishigami, Masatoshi
Kawashima, Hiroki
Yasuda, Satoshi
Shimose, Shigeo
Iwamoto, Hideki
Yamazoe, Taiji
Mori, Taizo
Kakazu, Eiji
Kawaguchi, Takumi
Toyoda, Hidenori
Kanto, Tatsuya
JOURNAL OF GASTROENTEROLOGY, 2023, 58 (06) : 565 - 574
[37] Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Yamauchi, Yurika
Saeki, Issei
Yamasaki, Takahiro
Egusa, Maho
Nishiyama, Natsuko
Fujioka, Tsuyoshi
Kawamoto, Daiki
Nishimura, Tatsuro
Tanabe, Norikazu
Oono, Takashi
Matsumoto, Toshihiko
Ishikawa, Tsuyoshi
Marumoto, Yoshio
Matsukuma, Satoshi
Shindo, Yoshitaro
Tokumitsu, Yukio
Yoshimine, Sota
Murakami, Junichi
Tanaka, Toshiki
Kimura, Sotai
Hoshii, Yoshinobu
Hamano, Kimikazu
Nagano, Hiroaki
Takami, Taro
HEPATOLOGY RESEARCH, 2023, 53 (07) : 681 - 686
[38] Identification of a predictive phosphoproteomic signature of response to atezolizumab and bevacizumab (AB) in patients with advanced hepatocellular carcinoma (aHCC)
Sarker, Debashis
Borek, Weronika E.
Pedicona, Federico
Zen, Yoh
Christopher, Josie A.
Karampera, Christina
Campbell, Amy
Khorsandi, Shirin Elizabeth
Dowe, Thomas
Habarwaa, Marwo
Britton, David James
Heaton, Nigel
Cutillas, Pedro Rodriguez
Williamson, Andrew
Dokal, Arran David
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[39] Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Persano, M.
Rimini, M.
Tada, T.
Suda, G.
Shimose, S.
Kudo, M.
Yoo, C.
Cheon, J.
Finkelmeier, F.
Lim, H. Y.
Presa, J.
Masi, G.
Bergamo, F.
Iavarone, M. A.
Cabibbo, G.
Foschi, F. G.
Piscaglia, F.
Cascinu, S.
Scartozzi, M.
Gardini, A. Casadei
ANNALS OF ONCOLOGY, 2023, 34 : S1535 - S1535
[40] Tumor steatosis and glutamine synthetase expression in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy
Kurebayashi, Yutaka
Tsujikawa, Hanako
Sugimoto, Katsutoshi
Yunaiyama, Daisuke
Araki, Yoichi
Saito, Kazuhiro
Takahashi, Hiroshi
Kakegawa, Tatsuya
Wada, Takuya
Tomita, Yusuke
Abe, Masakazu
Yoshimasu, Yu
Takeuchi, Hirohito
Hirata, Taiki
Sakamaki, Kentaro
Kakimi, Kazuhiro
Nagao, Toshitaka
Itoi, Takao
Sakamoto, Michiie
HEPATOLOGY RESEARCH, 2023, 53 (10) : 1008 - 1020

← 1 2 3 4 5 →